DLD Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.16M Buy
+20,000
New +$2.7M 0.21% 60
2022
Q1
Sell
-100,000
Closed -$11.2M 231
2021
Q4
$11.2M Buy
+100,000
New +$12.1M 0.6% 38
2020
Q1
Sell
-100,000
Closed -$9.52M 104
2019
Q4
$9.52M Buy
+100,000
New +$8.65M 0.51% 26

Other funds holding XBI

DLD Asset Management's XBI Position: Q4 2025 in Review

DLD Asset Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2025, closing a stake of 27,096 shares — an estimated $2.72M sold.

DLD Asset Management first reported a position in XBI in Q3 2025 and held it in 1 quarter. The position peaked at $2.72M in Q3 2025. 814 funds tracked by Wall St. Rank hold XBI as of Q4 2025.

  • DLD Asset Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2025 after selling out during the quarter.
  • DLD Asset Management sold 27,096 State Street SPDR S&P Biotech ETF shares in Q4 2025, an estimated $2.72M.
  • DLD Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2025 and held it in 1 quarter.
  • DLD Asset Management's State Street SPDR S&P Biotech ETF position peaked at $2.72M in Q3 2025.
  • 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2025.

Based on DLD Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.